SEC Form 4 · accession 0001123292-18-001085
Arbutus Biopharma Corp · ABUS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Frank Torti
Director
Period of report
Nov 26, 2018
Accepted (ET)
Nov 27, 2018 · 2:21 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001447028
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Director Share Option (right to buy)F1 | $4.72 | Nov 26, 2018 | A | 44,000 | A | — | Nov 26, 2028 | Common Shares | 44,000 | 44,000 | D |
Explanation of responses
- F1The option will vest and become exercisable in three equal annual installments beginning November 26, 2019.